An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer

Sponsor
Peking University
Study ID
NCT01860144
Status
Unknown

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.

Key Dates

First listed
May 22, 2013
Start date
Jun 30, 2012
Status verified
May 2015
Primary completion
Dec 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
250 participants (estimated)

Arms

  • Arm: bevacizumab
    Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab

Primary Outcome Measure

Objective response rate [ Time Frame: 6 weeks ]

Central Contacts

Related Studies